AIDS Therapies

Here Come the Chemokine-Receptor Antagonists

Published in AIDS Weekly, April 28th, 1997

The rapid pace of AIDS research again has accelerated with the announcement that a modified (beta)-chemokine can block HIV infection.

The naturally occurring (beta)-chemokines RANTES, MIP-1(alpha), and MIP-1(beta) inhibit HIV infection by primary and macrophage-tropic HIV-1 isolates (Cocchi et al., Science, 1995;270:1811-5), but they cannot prevent infection of primary macrophage cultures. Moreover, their use as AIDS therapies is limited by their natural functions of leukocyte activation and chemotaxis signalling.

Now an international research team reports that a modification to one of these cytokines, RANTES, causes it to completely block the CCR5...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-04-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry